Genome-wide methylation patterns predict clinical benefit of immunotherapy in lung cancer

BACKGROUND: It is crucial to unravel molecular determinants of responses to immune checkpoint blockade (ICB) therapy because only a small subset of advanced non-small cell lung cancer (NSCLC) patients responds to ICB therapy. Previous studies were concentrated on genomic and transcriptomic markers (...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jeong Yeon, Choi, Jung Kyoon, Jung, Hyunchul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410160/
https://www.ncbi.nlm.nih.gov/pubmed/32762727
http://dx.doi.org/10.1186/s13148-020-00907-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410160/
https://www.ncbi.nlm.nih.gov/pubmed/32762727
http://dx.doi.org/10.1186/s13148-020-00907-4

Ejemplares similares